PUBLIC COMPANY
savePLATINUM
USupdated 5mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Summit, BioNTech, more headline WCLC with next-gen lung cancer drugsBioNTech, Summit Therapeutics, GSK and Roche have made a splash at the ongoing World Conference on Lung Cancer taking place in South Korea. These companies and their partners have all shared new fi…biospace · 12d ago
- Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancerCullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…fiercebiotech · 15d ago
- STAT+: Cancer drug shortages keep disrupting patient carePlatinum chemotherapy's long-term effects, surprising heart failure drug failures, and more biotech news from The Readoutstat · 15d ago
- Boycott launched against American Diabetes Association includes journalTrump's $500 Obamacare promise, childhood cancer treatment with long-term risks, and more health newsstat · 15d ago
- STAT+: An AI tool aims to catch harder-to-detect heart attacks in EKGsA newly approved AI tool can scan EKGs for severe heart attacks and, the company says, for rarer patterns indicating blocked arteries.stat · 15d ago
- GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with MerckGSK’s risvutatug rezetecan has achieved a median overall survival of 18.5 months in a phase 3 trial, painting the antibody-drug conjugate as a threat to Amgen and Merck & Co. in the lung cancer field.fiercebiotech · 15d ago
- Platinum-based chemotherapy in childhood causes mutations that age the liverPlatinum chemotherapy aged the liver cells of treated children, making them look more like adult liver cells and possibly raising the long-term risk of new tumorsstat · 15d ago
- RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancerThe data, which come from a subgroup in an earlier trial that Truist Securities called “the most relevant” to Revolution Medicines’ ongoing Phase 3 test in RAS mutant NSCLC, showed a 42% overall re…biospace · 23d ago
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalTaiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…fiercebiotech · 1mo ago
- Summit, Merck must navigate new regulatory terrain in China-first cancer landscapeSummit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…biospace · 2mo ago
comments(0)
5-min edit window · permanent after that